<p><strong>Pediatric Use</strong>: The safety and effectiveness of Dabigatran Etexilate in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: Of the total number of patients in the RE-LY study, 82% were 65 and over, while 40% were 75 and over. The risk of stroke and bleeding increases with age, but the risk-benefit profile is favorable in all age groups.</p>